Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MediciNova halts Phase 2 trial
May 2018
SHARING OPTIONS:

LA JOLLA, Calif.—Early April saw MediciNova Inc. announce the early termination of its Phase 2 clinical trial of MN-001 in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with hypertriglyceridemia, due to positive results from the interim analysis. The compound significantly reduced mean serum triglycerides—a primary endpoint—from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment, with no clinically significant safety or tolerability issues. MediciNova plans to accelerate development of MN-001 given these results.
 
Dr. Yuichi Iwaki, president and CEO of MediciNova, remarked that, “We are thrilled with the results of this study, which showed a large reduction in triglycerides. Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.